Armata Pharmaceuticals, Inc. Common Stock (ARMP) Stock Price

ARMPStock

$3.37−3.44%52W

Market Cap$125.30M

P/E—

PEG Ratio—

Div yield—

Beta1.67

ARMP Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-83.74%

Price vs S&P 500 (4W)-19.57%

VGM Score40.91

Book Value / Share (Quarterly)$0.53

P/TBV (Annual)1.74x

Revenue Growth (3Y)-3.81%

Cash Flow / Share (Quarterly)$-0.69

Price vs S&P 500 (YTD)-58.26%

Net Profit Margin (TTM)-3467.04%

EPS (TTM)$-6.12

10-Day Avg Trading Volume0.11M

EPS Excl Extra (TTM)$-6.12

Revenue Growth (5Y)43.00%

EPS (Annual)$-4.80

ROI (Annual)-102.33%

Net Profit Margin (5Y Avg)-1324.46%

Cash / Share (Quarterly)$0.64

Revenue Growth QoQ (YoY)15.72%

ROA (Last FY)-226.06%

Revenue Growth TTM (YoY)-19.29%

EBITD / Share (TTM)$-0.91

ROE (5Y Avg)-117.52%

Operating Margin (TTM)-734.19%

Cash Flow / Share (Annual)$-0.72

P/B Ratio6.56x

P/B Ratio (Quarterly)2.16x

Net Income / Employee (Annual)$-2,849,200

EV / Revenue (TTM)69.43x

Net Interest Coverage (TTM)-0.27x

ROA (TTM)-235.69%

EPS Incl Extra (Annual)$-4.80

Current Ratio (Annual)1.19x

Quick Ratio (Quarterly)0.11x

3-Month Avg Trading Volume0.20M

52-Week Price Return-3.44%

Revenue / Employee (TTM)$90,900

Tangible BV / Share (Quarterly)$0.24

P/S Ratio (Annual)25.55x

Asset Turnover (Annual)0.06x

52-Week High$16.34

Operating Margin (5Y Avg)-740.17%

EPS Excl Extra (Annual)$-4.80

CapEx CAGR (5Y)-7.95%

Tangible BV CAGR (5Y)56.05%

26-Week Price Return-73.84%

Quick Ratio (Annual)1.02x

13-Week Price Return-25.28%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)0.11x

Enterprise Value$384.86M

Revenue / Share Growth (5Y)22.08%

Asset Turnover (TTM)0.07x

Book Value / Share Growth (5Y)-38.52%

Revenue / Employee (Annual)$80,400

Pretax Margin (Annual)-3544.03%

Cash / Share (Annual)$0.24

3-Month Return Std Dev117.93%

Net Income / Employee (TTM)$-3,150,500

ROE (Last FY)-102.33%

Net Interest Coverage (Annual)-0.15x

EPS Basic Excl Extra (Annual)$-4.80

Receivables Turnover (TTM)4.70x

Total Debt / Equity (Quarterly)1.38x

EPS Incl Extra (TTM)$-6.12

Receivables Turnover (Annual)4.17x

ROI (TTM)-81.23%

P/S Ratio (TTM)22.61x

Pretax Margin (5Y Avg)-1324.46%

Revenue / Share (Annual)$0.14

Tangible BV / Share (Annual)$0.71

Price vs S&P 500 (52W)-18.97%

Year-to-Date Return-46.34%

5-Day Price Return-7.16%

EPS Normalized (Annual)$-4.80

ROA (5Y Avg)-77.97%

Net Profit Margin (Annual)-3544.03%

Month-to-Date Return-8.17%

Cash Flow / Share (TTM)$-1.62

EBITD / Share (Annual)$-0.97

Operating Margin (Annual)-747.02%

LT Debt / Equity (Annual)0.38x

ROI (5Y Avg)-116.66%

LT Debt / Equity (Quarterly)0.38x

EPS Basic Excl Extra (TTM)$-6.12

P/TBV (Quarterly)4.68x

P/B Ratio (Annual)1.24x

Pretax Margin (TTM)-3467.04%

Book Value / Share (Annual)$1.00

Price vs S&P 500 (13W)-27.96%

Beta1.67x

Revenue / Share (TTM)$0.09

ROE (TTM)-120.00%

52-Week Low$2.75

vGradeD

gGradeC

mGradeC

vgmGradeC

ARMP Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 12, 2026	-$0.45	$1.20	+368.54%(+$1.64)
Q1 2026	May 13, 2026	-$0.38	-$3.16	-731.58%(-$2.78)
Q4 2025	Mar 25, 2026	-$0.19	-$0.36	-89.94%(-$0.17)
Q3 2025	Nov 12, 2025	-$0.42	-$0.33	+20.93%(+$0.09)
Q2 2025	Aug 12, 2025	-$0.39	-$0.29	+25.30%(+$0.10)

ARMP Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.13

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ARMPArmata Pharmaceuticals, Inc. Common Stock	D	C	C	22.6x	-19.3%	—	—	$3.37
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals develops bacteriophage therapeutics to treat antibiotic-resistant bacterial infections using proprietary phage-based technology. The company has clinical-stage candidates targeting major pathogens including Pseudomonas aeruginosa and Staphylococcus aureus, with additional programs in development. Armata is also collaborating with Merck on synthetic phage candidates for an undisclosed infectious disease target, diversifying its pipeline across difficult-to-treat infections.